Best Penny Stocks Under 10 Cents Right Now → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. These penny stocks all have a super-low share price of $0.10 or less and are sorted by average trading volume in dollars. These companies are considered the most actively-traded stocks priced under $0.10. Show: Stocks Under $0.50 Stocks Under $1.00 Stocks Under $2.00 Stocks Under $5.00 Stocks Under $10.00 Stocks Under $20.00 Stocks Under $30.00 Stocks Under $50.00 Stocks On Sale #1 - FiskerNYSE:FSRStock Price: $0.09 (-$0.04)P/E Ratio: -0.04Market Cap: $31.45 millionAverage Trading Volume: 167.01 million sharesConsensus Rating: Reduce (1 Buy Ratings, 4 Hold Ratings, 4 Sell Ratings)Consensus Price Target: $2.76 (2,973.7% Upside)Fisker Inc. develops, manufactures, markets, leases, or sells electric vehicles. It operates through three segments: The White Space, The Value Segment, and The Conservative Premium segments. The company is also involved in asset-light automotive business. In addition, it offers fisker flexible platform agnostic design, a process that develops and designs electric vehicles in specific segment size. The company was incorporated in 2016 and is headquartered in Manhattan Beach, California. Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. #2 - Sunshine BiopharmaNASDAQ:SBFMStock Price: $0.06P/E Ratio: -0.03Market Cap: $1.60 millionAverage Trading Volume: 42.11 million sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.60 (4,461.4% Upside)Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents. It also offers Essential 9, an amino acids capsules; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. Sunshine Biopharma, Inc. is based in New York, New York.#3 - Kintara TherapeuticsNASDAQ:KTRAStock Price: $0.09P/E Ratio: -0.02Market Cap: $3.51 millionAverage Trading Volume: 11.52 million sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AKintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.#4 - WiSA TechnologiesNASDAQ:WISAStock Price: $0.02Market Cap: $780,000.00Average Trading Volume: 43.57 million sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AWiSA Technologies, Inc. develops, manufactures, and sells audio wireless technology for smart devices and next-generation home entertainment systems in the United States and Europe. The company offers wireless modules. It serves primarily to consumer electronics companies. The company was formerly known as Summit Wireless Technologies, Inc. and changed its name to WiSA Technologies Inc. in March 2022. WiSA Technologies, Inc. was incorporated in 2010 and is headquartered in Beaverton, Oregon.#5 - AtrecaNASDAQ:BCELStock Price: $0.08 (-$0.01)P/E Ratio: -0.03Market Cap: $2.97 millionAverage Trading Volume: 8.69 million sharesConsensus Rating: Hold (1 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $10.75 (14,233.3% Upside)Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.#6 - LumiraDxNASDAQ:LMDXStock Price: $0.01P/E Ratio: -0.01Market Cap: $2.42 millionAverage Trading Volume: 56.75 million sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $1.75 (22,926.3% Upside)LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.the most reliable asset on earth is making a comeback (Ad)Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here#7 - Pineapple EnergyNASDAQ:PEGYStock Price: $0.06P/E Ratio: -0.04Market Cap: $2.67 millionAverage Trading Volume: 5.68 million sharesConsensus Rating: Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.00 (6,351.6% Upside)Pineapple Energy Inc. engages in the sale, design, and installation of photovoltaic solar energy systems and battery storage systems in the United States. Its brand portfolio includes SUNation, Hawaii Energy Connection, E-Gear, Sungevity, and Horizon Solar Power. The company develops and manufactures energy management software and hardware, such as energy management control devices on solar systems that are paired with batteries. It primarily serves residential homeowners, as well as commercial owners, other municipal customers, energy services companies, and other utilities. Pineapple Energy Inc. was founded in 1969 and is based in Minnetonka, Minnesota.#8 - InvitaeNYSE:NVTAStock Price: $0.01P/E Ratio: 0.00Market Cap: $3.47 millionAverage Trading Volume: 23.72 million sharesConsensus Rating: Strong Sell (0 Buy Ratings, 0 Hold Ratings, 3 Sell Ratings)Consensus Price Target: $1.00 (7,592.3% Upside)Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.#9 - Gamida CellNASDAQ:GMDAStock Price: $0.06 (-$0.28)P/E Ratio: -0.20Market Cap: $6.25 millionAverage Trading Volume: 4.89 million sharesConsensus Rating: Moderate Buy (3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.75 (7,923.6% Upside)Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.#10 - Tritium DCFCNASDAQ:DCFCStock Price: $0.06Market Cap: $9.47 millionAverage Trading Volume: 4.48 million sharesConsensus Rating: Hold (0 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $1.50 (2,578.6% Upside)Tritium DCFC Limited designs, manufactures, and supplies direct current chargers for electric vehicles in Australia and internationally. The company's charging station hardware portfolio includes various standalone chargers and distributed chargers. Its service and maintenance portfolio includes warranties, service level agreements, and sales of spare parts. The company operates a service management software platform; and provides high-power charging sessions. It serves charge point operators, automakers, electric vehicle fleets, and fuel stations, as well as retail and utility sectors. Tritium DCFC Limited was founded in 2001 and is based in Murarrie, Australia.#11 - Charge EnterprisesNASDAQ:CRGEStock Price: $0.01P/E Ratio: -0.03Market Cap: $1.51 millionAverage Trading Volume: 32.32 million sharesConsensus Rating: Moderate Buy (1 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $4.50 (64,185.7% Upside)Charge Enterprises Inc. operates as an electrical, broadband, and electric vehicle (EV) charging infrastructure company. The company provides clients with end-to-end project management services, including advising, designing, engineering, acquiring and installing equipment, monitoring, servicing, and maintenance. It operates in two segments, Infrastructure and Telecommunications. The Infrastructure segment offers broadband and wireless, electrical contracting, electric vehicle charging, and fleet services. The Telecommunications segment provides internet-protocol-based and time-division multiplexing access for transport of long-distance voice and data minutes; domestic switching and related peripheral equipment services, and carrier-grade routers and switches for internet and circuit-based services, as well as connection of voice calls and data services. The company was formerly known as TransWorld Holdings Inc and changed its name to Charge Enterprises, Inc. in January 2021. Charge Enterprises, Inc. was incorporated in 2003 and is based in New York, New York. On March 7, 2024, Charge Enterprises, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Altcoin FRENZY Alert… (Ad)Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!)#12 - Sintx TechnologiesNASDAQ:SINTStock Price: $0.05Market Cap: $269,000.00Average Trading Volume: 3.74 million sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/ASintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.#13 - Greenbrook TMSNASDAQ:GBNHStock Price: $0.05P/E Ratio: -0.02Market Cap: $1.96 millionAverage Trading Volume: 3.60 million sharesConsensus Rating: Moderate Buy (2 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.00 (6,150.0% Upside)Greenbrook TMS Inc., together with its subsidiaries, controls and operates a network of outpatient mental health services centers in the United States. Its centers specialize in the provision of transcranial magnetic stimulation (TMS) therapy, an FDA-cleared non-invasive therapy for the treatment of major depressive disorder and other mental health disorders, as well as related psychiatric services. As of December 31, 2021, the company operated 94 wholly owned and 55 TMS centers in the commonwealth of Virginia and the States of Maryland, Delaware, North Carolina, Missouri, Illinois, Ohio, Texas, Connecticut, Florida, South Carolina, Michigan, Alaska, Oregon, California, Iowa, and Massachusetts. Greenbrook TMS Inc. was founded in 2011 and is headquartered in Toronto, Canada.#14 - Blue Star FoodsNASDAQ:BSFCStock Price: $0.09 (-$0.01)P/E Ratio: -0.01Market Cap: $1.56 millionAverage Trading Volume: 1.66 million sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $20.00 (22,246.4% Upside)Blue Star Foods Corp., through its subsidiaries, operates as a marine protein company in the United States and Canada. The company imports, packages, and sells refrigerated pasteurized various crab meats sourced primarily from Southeast Asia; and other premium seafood products. It sells its products primarily to food service distributors, as well as wholesalers, retail establishments, and seafood distributors under the Blue Star, Pacifika, Oceanica, Crab & Go Premium Seafood, Lubkin, First Choice, Good Stuff, Coastal Pride Fresh, and Little Cedar Falls brands. Blue Star Foods Corp. was formerly known as John Keeler & Co. Inc. The company was incorporated in 1995 and is based in Miami, Florida.#15 - WeWorkNYSE:WEStock Price: $0.08 (-$0.18)P/E Ratio: 0.00Market Cap: $3.99 millionAverage Trading Volume: 1.61 million sharesConsensus Rating: Hold (0 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $8.00 (10,566.7% Upside)WeWork Inc. provides flexible workspace solutions to individuals and organizations worldwide. The company offers workstation, private office, and customized floor solutions; and various amenities and services, such as private phone booths, internet, high-speed business printers and copiers, mail and package handling, front desk services, off-peak building access, common areas, and daily enhanced cleaning solutions. It also provides various value-add services; business and technical service solutions, including professional employer organization and payroll services, remote workforce solutions, human resources benefits, dedicated bandwidth, and IT equipment co-location solutions. In addition, the company offers WeWork All Access, a monthly subscription-based model that allows members to book workspaces, conference rooms, and private offices; WeWork On Demand, which enables users with pay-as-you-go access to book individual workspace or conference rooms at nearby WeWork locations; and WeWork Workplace, a turnkey workspace management solution for landlords, operators, and enterprises. WeWork Inc. was founded in 2010 and is headquartered in New York, New York.#16 - JOANNNASDAQ:JOANStock Price: $0.10 (-$0.01)P/E Ratio: -0.02Market Cap: $4.06 millionAverage Trading Volume: 1.22 million sharesConsensus Rating: Hold (0 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $1.06 (996.5% Upside)JOANN Inc. operates as a specialty retailer of sewing and fabrics, and arts and crafts category products in the United States. The company products in sewing category include cotton fabrics; warm fabrics, such as fleece and flannel fabrics; home decorating and utility fabrics and accessories; fashion and sportswear fabrics; special occasion fabrics; pillow forms; stuffing, batting, and foams; seasonally themed and licensed fabric designs; and sewing construction supplies comprising cutting implements, threads, zippers, trims, tapes, pins, elastic, and buttons, as well as patterns for sewing projects. Its products in arts and crafts, home décor, and other categories consist of yarn and yarn accessories, and needlecraft kits and supplies; paper crafting components; craft materials; fine art materials; sewing machines, craft technology, lighting, irons, organizers, and other products; artificial floral products; seasonal décor and entertaining products; home décor accessories; ready-made frames; comprehensive assortment books and magazines; and non-merchandise services. The company offers its products through retail stores, as well as online. The company was formerly known as Jo-Ann Stores Holdings Inc. and changed its name to JOANN Inc. in February 2021. JOANN Inc. was founded in 1943 and is based in Hudson, Ohio. On March 18, 2024, JOANN Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Altcoin FRENZY Alert… (Ad)Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… Click here now to register for the event (FOR FREE!)#17 - MovellaNASDAQ:MVLAStock Price: $0.08 (-$0.02)Market Cap: $3.85 millionAverage Trading Volume: 1.38 million sharesConsensus Rating: Buy (3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $2.45 (3,123.7% Upside)Movella Holdings Inc. operates as a full-stack provider of sensors, software, and analytics that enable the digitization of movement in the United States. Its real-time character movement in digital environments transforms movement into digital data that provides actionable insights. The company offers Xsens 3D Body Motion Systems comprises wearable sensor systems and motion capture solutions, including MVN Animate or MVN Analyze software, a full-body wearable sensor system, which captures the motion of the human body. It also provides Xsens sensor modules that enables customers to accelerate the development of motion-based applications; and DOT wearables for analysis and reporting of human kinematics. In addition, the company offers Kinduct human performance platform that provides biomechanical, biometric, and objective data for athletic performance, wellness, and injury risk. It serves the entertainment, health and sports, and automation and mobility markets. Movella Holdings Inc. is based in Henderson, Nevada.#18 - Better TherapeuticsNASDAQ:BTTXStock Price: $0.01P/E Ratio: -0.01Market Cap: $648,000.00Average Trading Volume: 6.89 million sharesConsensus Rating: Moderate Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $6.00 (46,053.8% Upside)Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.#19 - CURO GroupNYSE:CUROStock Price: $0.09 (+$0.03)P/E Ratio: -0.01Market Cap: $3.72 millionAverage Trading Volume: 743,303 sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $3.00 (3,233.3% Upside)CURO Group Holdings Corp., together with its subsidiaries, provides consumer finance products in the United States and Canada. The company offers secured and unsecured installment loans, revolving line of credit, and single-pay loans; and credit protection insurance, check cashing, money transfer, foreign currency exchange, and other ancillary financial products and services, as well as reloadable prepaid debit cards and demand deposit accounts. The company also provides loans through online. It operates under the Covington Credit, Heights Finance, Quick Credit, Southern Finance, First Heritage Credit, Cash Money, LendDirect, and Flexiti brands. The company was formerly known as Speedy Group Holdings Corp. and changed its name to CURO Group Holdings Corp. in May 2016. CURO Group Holdings Corp. was founded in 1997 and is headquartered in Chicago, Illinois.#20 - DMK PharmaceuticalsNASDAQ:DMKStock Price: $0.05 (-$0.02)Market Cap: $505,000.00Average Trading Volume: 1.16 million sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $1.50 (2,900.0% Upside)DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California.#21 - First Mining GoldOTCMKTS:FFMGFStock Price: $0.09Average Trading Volume: 536,781 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: $0.70 (700.0% Upside)First Mining Gold Corp. develops and explores for gold projects. It also explores for silver and copper deposits. The company primarily holds interests in the Springpole Gold Project located in northwestern Ontario. First Mining Gold Corp. was founded in 2015 and is headquartered in Vancouver, Canada.#22 - BZAMOTCMKTS:BZAMFStock Price: $0.04P/E Ratio: -0.08Market Cap: $8.14 millionAverage Trading Volume: 506,297 sharesConsensus Rating: Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/ABZAM Ltd. operates as a cannabis producer with a focus on branded consumer goods. Its brands include the BZAM, TGOD, ness, Highly Dutch Organic, and TABLE TOP, as well as Dunn Cannabis, FRESH, and Wyld partner brands. The company operate facilities in British Columbia, Alberta, Ontario, and Quebec, as well as retail stores in Winnipeg, Manitoba and Regina, Saskatchewan. The company was formerly known as The Green Organic Dutchman Holdings Ltd. and changed its name to BZAM Ltd. in February 2023. The company was incorporated in 2016 and is headquartered in Vancouver, Canada.#23 - Evofem BiosciencesNASDAQ:EVFMStock Price: $0.03 (+$0.01)Market Cap: $1.19 millionAverage Trading Volume: 823,889 sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/AEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women; and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.#24 - Nevada CopperOTCMKTS:NEVDFStock Price: $0.07Average Trading Volume: 268,640 sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/ANevada Copper Corp. engages in the exploration, development, and operation of mineral properties in Nevada. The company explores for copper, iron magnetite, gold, and silver ores. It holds 100% interests in the Pumpkin Hollow property that consist of approximately 24,300 acres of contiguous mineral rights located in northwestern Nevada, the United States. Nevada Copper Corp. was incorporated in 1999 and is based in Vancouver, British Columbia.#25 - SQZ BiotechnologiesOTCMKTS:SQZBStock Price: $0.05P/E Ratio: -0.02Market Cap: $1.37 millionAverage Trading Volume: 239,033 sharesConsensus Rating: Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)Consensus Price Target: N/ASQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts. More Stock Ideas from MarketBeat Stock Lists: 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks: Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange: NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEMKT Stocks NYSEARCA Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas: GameStop Stock Downtrend Is Intact: The End Game Draws Near Trump Media & Technology Group Soars on Market Debut 3 Stocks Insiders Are Buying That Analysts Love Should You Buy Boeing Stock After CEO Resignation Announcement? These Are The Most Upgraded Stocks From Q1 4 Overbought Household Names, Time for a Pullback? Top 3 Stocks Bought By Members of Congress In the First Quarter UiPath Cuts Q1 and Raises Full Year Guidance Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.